OBI Pharma to Sponsor Adagloxad Simolenin Satellite Symposium at the 2016 ESMO Annual Meeting
2016.Sep.03
未分類
Corporate
Michael Chang: “the U.S. Department of Justice Had Already Proven My Innocence”
2016.Aug.11
未分類
Corporate
Dr. Nathan Chen leaves OBI Pharma; Accepts New Role on Company’s Medical Advisory Board
2016.Jul.27
未分類
Corporate
Quick Takes on Promising New Approaches to Treating Breast Cancer
2016.Jul.26
未分類
Corporate
ASCO KOL interviews: Dr. Hope Rugo／Dr. James C. Paulson
2016.Jun.05
未分類
Corporate
OBI Pharma Presents Data for Novel Investigational OBI-822/OBI-821 in Patients with Metastatic Breast Cancer at the 2016 American Society of Clinical Oncology Annual Meeting
2016.May.19
未分類
Corporate
OBI’s Abstract at ASCO 2016: Randomized Phase 2/3 Trial of Active Immunotherapy With OPT-822/OPT-821 in Patients With Metastatic Breast Cancer
2016.May.19
未分類
Corporate
OBI Pharma to Present New Data at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
2016.May.13
未分類
Corporate
Company Position Statement Regarding Recent Investigation of Senior Executives
2016.Mar.31
未分類
Corporate
OBI Pharma Announces Decision By ASCO to Accept its Abstract for Oral Presentation at ASCO’S 2016 Annual Meeting
